Age-related macular degeneration

3 trials MedDRA PT
3 Registered trials
0 Recruiting
3 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 1
S Ophthalmology/ENT (ATC S) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Monoclonal antibody 1 substance
Phase II/III: 1 Phase III/IV: 1 Phase IV: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II/III

1 trial

Phase III/IV

1 trial
  • Consorci Mar Parc De Salut De Barcelona Academic
    BEVACIZUMAB
    2024-518990-33-00 1 country n=574
    Pending

Phase IV

1 trial
  • Medical University Of Graz Academic
    FARICIMAB
    2024-514408-15-00 1 country 2024 n=50
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Eyebiotech Limited Commercial 1 Phase II/III 0
Consorci Mar Parc De Salut De Barcelona Academic 1 Phase III/IV 0
Medical University Of Graz Academic 1 Phase IV 0
New trials by year
2024
1
← All indication landscapes